Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Boehringer Ingelheim
Baxter
Colorcon
Moodys

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 6,572,866

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,572,866
Title: Nerve growth factor as a vaccine adjuvant
Abstract:A vaccination method utilizes a pharmaceutical combination for enhancing vaccine effectiveness. The method utilizes an immune response-triggering vaccine capable of stimulating production in an immunodeficient animal antibodies to a disease-causing agent foreign to the animal. As an adjuvant, a vaccine effectiveness-enhancing amount of Nerve Growth Factor (NGF) is administered, which enhances production and affinity of the antibodies in the animal, in response to the vaccine.
Inventor(s): Torcia; Maria (Florence, IT)
Assignee: Protechtion Unlimited, Inc. (Wilmington, DE)
Application Number:09/269,883
Patent Claims:1. A pharmaceutical combination for enhancing vaccine effectiveness in immunodeficient animals, comprising: A) an immune response-triggering vaccine capable of stimulating production in an animal of antibodies to a disease-causing agent foreign to said animal; and B) a vaccine effectiveness-enhancing amount of Nerve Growth Factor (NGF), which enhances production of said antibodies in said animal, in response to said vaccine; C) wherein said animal is an immunodeficient animal, and wherein said vaccine and said NGF can be administered separately or together.

2. The pharmaceutical combination of claim 1, wherein said vaccine is in an amount of from about 1.times.10.sup.-9 g to about 1.times.10.sup.-3 g, and said NGF is in an amount of about 0.001-100 mg/kg.

3. The pharmaceutical combination of claim 1, wherein said vaccine is in an amount of from about 1.times.10.sup.-8 g to about 1.times.10.sup.-4 g, and said NGF is in an amount of about 0.1-10 mg/kg.

4. The pharmaceutical combination of claim 1, wherein said NGF is in an amount of about 0.3-3 mg/kg.

5. The pharmaceutical combination of claim 1, comprising a composition including said vaccine and said NGF.

6. The pharmaceutical combination of claim 5, wherein said composition includes a pharmaceutically acceptable carrier.

7. A vaccination method comprising administering to an immunodeficient animal a pharmaceutical combination for enhancing vaccine effectiveness, said pharmaceutical combination comprising: A) an immune response-triggering vaccine capable of stimulating production in an animal of antibodies to a disease-causing agent foreign to said animal; and B) a vaccine effectiveness-enhancing amount of Nerve Growth Factor (NGF), which enhances production of said antibodies in said animal, in response to said vaccine; C) wherein said animal is an immunodeficient animal, wherein said vaccine and said NGF can be administered separately or together, and wherein effectiveness of said vaccine in said animal is enhanced by said NGF.

8. The method of claim 7, wherein said animal is human, and said vaccine is selected from the group consisting of Influenza vaccine, Hemophilus influenzae vaccine, Hepatitis A virus vaccine, Hepatitis B virus vaccine, Hepatitis C virus vaccine, Tuberculosis vaccine, Herpes-Zoster virus vaccine, Cytomegalovirus vaccine, Pneumococcal pneumonia vaccine, Meningococcal meningitis vaccine, Diphtheria vaccine, Tetanus vaccine, Rabies vaccine, Helicobacter pylori vaccine, polio vaccine and smallpox vaccine.

9. The method of claim 7, wherein said vaccine is in an amount of from about 1.times.10.sup.-9 g to about 1.times.10.sup.-3 g, and said NGF is in an amount of about 0.001-100 mg/kg.

10. The method of claim 7, wherein said vaccine is in an amount of from about 1.times.10.sup.-8 g to about 1.times.10.sup.-4 g, and said NGF is in an amount of from about 0.1-10 mg/kg.

11. The method of claim 7, wherein said NGF is in an amount of about 0.3-3 mg/kg.

12. The method of claim 7, wherein said vaccine is administered as a booster dose of vaccine.

13. The method of claim 12, wherein said NGF is administered about 3-4 days prior to said booster dose of vaccine.

14. The method of claim 12, wherein said NGF also is administered substantially concurrently with administration of said vaccine.

15. The method of claim 7, wherein said vaccine and said NGF are administered by injection.

16. A vaccination method comprising: administering to an immunodeficient animal a first dose of an immune response-triggering vaccine capable of stimulating production in an animal of antibodies to a disease-causing agent foreign to said animal; then, within a time period of between about 1 week and about 2 months after administration of said first dose, administering to said animal either 1) a vaccine effectiveness-enchancing amount of Nerve Growth Factor (NGF) which enhances production of said antibodies in said animal in response to said vaccine or 2) booster dose of said vaccine, along with a vaccine effectiveness-enhancing amount of said Nerve Growth Factor (NGF), so as to enhance effectiveness of said vaccine in said animal.

17. The method of claim 16 wherein said time period is about 10-45 days.

18. The method of claim 16 wherein said time period is about 10-30 days.

19. The method of claim 16 wherein said time period is about 10-20 days.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Merck
Johnson and Johnson
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.